## Abstract Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extran
Achromatic neurons in the cortex of progressive supranuclear palsy
โ Scribed by I. R. A. Mackenzie; L. P. Hudson
- Publisher
- Springer-Verlag
- Year
- 1995
- Tongue
- English
- Weight
- 895 KB
- Volume
- 90
- Category
- Article
- ISSN
- 0001-6322
No coin nor oath required. For personal study only.
โฆ Synopsis
Achromatic neurons (AN) in the cerebral cortex are a characteristic feature of several neurodegenerative conditions including Pick's disease, corticobasal degeneration and some cases of primary progressive aphasia. Although AN are occasionally seen in some other diseases, their presence in progressive supranuclear palsy (PSP) has not been previously documented. We found significant numbers of AN in the cerebral cortex of five out of seven cases which had been diagnosed pathologically as PSP. The identification of AN was greatly facilitated by the use of neurofilament immunohistochemistry. The entorhinal and transentorhinal cortices were most frequently involved, but in several cases AN were also seen throughout the neocortex. The presence and number of AN roughly correlated with a history of clinical dementia. This suggests that cortical AN may be a common and important pathological finding in PSP.
๐ SIMILAR VOLUMES
## Abstract Diagnostic accuracy has been addressed previously for Parkinson's disease in a brain bank collection, but accuracy of progressive supranuclear palsy (PSP) has not been addressed in a similar setting. Clinical and genetic features of pathologically confirmed cases of PSP were compared wi
## Abstract There have been few reports of the prevalence of progressive supranuclear palsy (PSP): the present study examines its prevalence in Japan and compares the findings with those in Europe and the United States. The prevalence per 100,000 was 5.82 (men, 9.14; women, 2.75), and the 95% confi